New malaria vaccine shows promise in preclinical trials

International research team used CLS to map structure of human antibodies bound to their prototype vaccine.

Malaria is caused by a parasite that is spread to humans by infected mosquitoes. In 2024, almost 282 million people worldwide were infected and 610,000 died, according to the World Health Organization. Malaria is a leading cause of death in children under the age of five.

Using the Canadian Light Source (CLS) at the University of Saskatchewan, an international team involving researchers from Canada, the US, and the Netherlands have developed a novel vaccine that is showing considerable promise in preclinical trials.Video: New malaria vaccine shows promise in preclinical trials

“Our long-term goal is to eliminate malaria by designing a vaccine that is more effective than the ones currently on the market,” says lead author Danton Ivanochko, a researcher at the Hospital for Sick Children (SickKids) in Toronto.

When the researchers examined blood samples from people with naturally acquired immunity to malaria, they were able to identify which proteins on the parasite play the largest role in transmission.

Read more on the CLS website

Structural surprise in motor protein may point to new strategies for controlling disease

Motor proteins are tiny “machines” inside cells that use chemical energy to move along molecular tracks and carry out essential processes like chromosome segregation during cell division. When a cell splits to make two new cells (called daughter cells), it carefully shares its instructions (chromosomes) so each new cell knows how to grow and work properly.

A group of motor proteins known as kinesin-8 proteins helps regulate how chromosomes are distributed between daughter cells — a process that, when disrupted, can lead to genomic instability. This instability is a key factor in the development of many diseases, including cancer.

“You can think of kinesins as tiny robots walking along train tracks to help organize and move chromosomes during cell division,” says John Allingham, professor and associate head of research in the Department of Biomedical and Molecular Sciences at Queen’s University.

While most research on kinesins has focused on the “feet” or motor domains — regions that walk along microtubule tracks — Allingham’s group turned their attention to the less-studied “body” or stalk region, which connects the feet and enables them to work together.

Recently, Allingham and his colleagues determined the structure of the stalk region of the fungal kinesin-8 protein Kip3, using Canada’s only synchrotron research facility, the Canadian Light Source (CLS) at the University of Saskatchewan. Their findings, published in Structure, reveal an unexpected architecture that could reshape our understanding of how kinesin-8 proteins assemble and function.

“What we expected to find was a long, coiled structure typical of other kinesin families,” says Allingham. “Instead, we discovered that this region folds into a compact helical bundle — more like a folded camping chair than a long, flexible pole.”

Read more on the CLS website

Image: John Allington (far right) and his research team

Credit: CLS